基线18F-FDG PET/CT对接受奥希替尼治疗的IV期非小细胞肺癌患者的预后价值
本研究回顾性分析177例接受奥希替尼治疗的IV期非小细胞肺癌患者,评估基线18F-FDG PET/CT代谢参数对无进展生存期(PFS)的预测价值。单因素分析显示SUVmax、SUVmean、MTV和TLG与PFS显著相关,多因素分析表明MTV是PFS的独立预后因素(HR=2.323,P=0.012)。
要点
- 基线MTV是接受奥希替尼治疗的IV期NSCLC患者PFS的独立预后因素(HR=2.323,P=0.012)。
- 单因素分析中SUVmax、SUVmean、MTV、TLG均与PFS显著相关, cutoff值分别为12.3、8.57、13.49 cm³、162.37。
- 基线PET/CT代谢参数可能有助于识别可从奥希替尼治疗中获益的NSCLC患者。
核心结论
- 基线18F-FDG PET/CT代谢参数可能有助于识别可从奥希替尼治疗中获益的NSCLC患者。
- 原发肿瘤基线MTV是接受奥希替尼治疗的IV期NSCLC患者PFS的可靠预后指标。
研究设计与样本
- 回顾性分析177例接受奥希替尼治疗并在治疗前接受18F-FDG PET/CT扫描的NSCLC患者(男98例,女79例;平均年龄58.5±11.0岁)。
- 评估临床和PET/CT参数包括年龄、性别、吸烟史、脑转移、骨转移、CEA水平、SUVmax、SUVmean、SUVpeak、MTV和TLG。
- 采用ROC曲线分析计算所有参数的最佳截断值,采用log-rank检验、Kaplan-Meier曲线和Cox比例风险模型分析PFS。
主要发现
- 平均随访时间为15.24±8.14个月。
- 单因素分析显示SUVmax(截断值12.3)与PFS显著相关,HR=1.776(P=0.007)。
- 单因素分析显示SUVmean(截断值8.57)与PFS显著相关,HR=2.155(P<0.001)。
- 单因素分析显示MTV(截断值13.49 cm³)与PFS显著相关,HR=3.312(P<0.001)。
- 单因素分析显示TLG(截断值162.37)与PFS显著相关,HR=3.370(P<0.001)。
关键数值与推荐
- SUVmax最佳截断值为12.3。
- SUVmean最佳截断值为8.57。
- MTV最佳截断值为13.49 cm³。
- TLG最佳截断值为162.37。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to evaluate the role of various metabolic parameters derived from baseline 18 F-FDG PET/CT in predicting the prognosis of stage IV non-small cell lung cancer (NSCLC) patients scheduled to receive osimertinib treatment. PATIENTS AND METHODS: A retrospective analysis was conducted on 177 NSCLC patients (98 males, 79 females; mean age 58.5 ± 11.0 y) who underwent osimertinib therapy and 18 F-FDG PET/CT scanning before treatment. Clinical and PET/CT parameters were assessed, including age, sex, smoking history, brain metastasis, bone metastasis, CEA level, SUVmax, SUVmean, SUVpeak, metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Receiver operating characteristic (ROC) curve analysis was used to calculate the optimal cutoff values for all parameters. Progression-free survival (PFS) was analyzed using log-rank tests, Kaplan-Meier curves, and Cox proportional hazard models to identify prognostic markers. RESULTS: The mean follow-up period was 15.24 ± 8.14 months. Univariate analysis revealed that SUVmax, SUVmean, MTV, and TLG were significantly associated with PFS, with cutoff values of 12.3, 8.57, 13.49 cm 3 , and 162.37, respectively. The hazard ratios were 1.776 ( P = 0.007), 2.155 ( P <0.001), 3.312 ( P < 0.001), and 3.370 ( P < 0.001), respectively. Multivariate survival analysis indicated that MTV was an independent prognostic factor for PFS (HR = 2.323; P = 0.012). CONCLUSIONS: Baseline PET/CT metabolic parameters before osimertinib treatment may help identify potential NSCLC patients who could derive clinical benefit, and baseline MTV of the primary tumor from 18 F-FDG PET/CT is a reliable prognostic indicator for PFS in stage IV NSCLC patients treated with osimertinib.
引用
- Jiang ZP, Shan HM, Zhu HY, et al. The Prognostic Value of Baseline 18 F-FDG PET/CT in Stage IV Non-Small Cell Lung Cancer Patients Receiving Osimertinib Treatment. Clin Nucl Med. 2025. PMID: 40658988. doi:10.1097/RLU.0000000000006039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。